Understand Business Like AI

Training Example: ENHERTU (Daiichi Sankyo, Inc.) – Review the Data, Give Your Score & Compare to the Real AI Evaluation

Industry Context — Common BS Fingerprints in Medical Devices, Pharma & Biotech
Generic Claims: advancing human health, breakthrough innovation, life-changing therapies, transforming patient outcomes…
Red Flags: FDA cleared used interchangeably with FDA approved, clinical claims without published study citations, breakthrough claims for incremental improvements, regulatory status implied but not specified…
Semantic Drift Patterns: homepage claims breakthrough but pipeline page shows preclinical only, FDA approved claims but only for one indication, marketed broadly, claims clinical evidence but links to poster presentations not published studies, claims global reach but regulatory approvals are single-market…
Proof Expectations: specific regulatory clearance numbers (FDA 510(k), CE, TGA), published clinical trial results with ClinicalTrials.gov registration, ISO 13485 and GMP certification details, peer-reviewed publication citations…

ENHERTU (Daiichi Sankyo, Inc.)

(https://enhertu.com) 📸 Data Snapshot: June 20, 2026

Analyze the raw signals below. How would a machine score this business’s credibility?

Here are the exact signals captured from up to six pages of the site — the same raw inputs the evaluation engine analyzed. They are grouped by signal type so you can weigh each the way the machine does.

🏗️ Semantic Structure — heading hierarchy & page identity (Info Density · Commodity Fingerprint)
HOMEPAGE ENHERTU® (fam-trastuzumab deruxtecan-nxki) | Official Patient Website (https://enhertu.com)
Title

ENHERTU® (fam-trastuzumab deruxtecan-nxki) | Official Patient Website

Meta

Learn more about ENHERTU® (fam-trastuzumab deruxtecan-nxki) for several types of cancer. See Full Safety and Boxed WARNINGS for more information.

H1 ENHERTU is FDA-approved for the treatment of several types of cancer
HEADER_REPEATED ENHERTU® (fam-trastuzumab deruxtecan-nxki) | Official Patient Website (https://enhertu.com/en/)
Title

ENHERTU® (fam-trastuzumab deruxtecan-nxki) | Official Patient Website

Meta

Learn more about ENHERTU® (fam-trastuzumab deruxtecan-nxki) for several types of cancer. See Full Safety and Boxed WARNINGS for more information.

H1 ENHERTU is FDA-approved for the treatment of several types of cancer
BODY ENHERTU® (fam-trastuzumab deruxtecan-nxki) | HER2+ Metastatic Breast Cancer Patient Site (https://enhertu.com/en/breast/)
Title

ENHERTU® (fam-trastuzumab deruxtecan-nxki) | HER2+ Metastatic Breast Cancer Patient Site

Meta

Find valuable information about ENHERTU® (fam-trastuzumab deruxtecan-nxki), including clinical trial results, safety information, downloadable resources, and more. See the full Important Safety Information, Prescribing Information, including Boxed WARNINGS, and Medication Guide for more information.

H1 Sure, HER2-positive metastatic breast cancer will try to take it all. But
H3 Select a Cancer Type
H3 What is the most important information I should know about ENHERTU?
H3 ENHERTU can cause serious side effects, including:
BODY ENHERTU® (fam-trastuzumab deruxtecan-nxki) | Metastatic Breast Cancer Patient Site (https://enhertu.com/en/her2-low-breast/)
Title

ENHERTU® (fam-trastuzumab deruxtecan-nxki) | Metastatic Breast Cancer Patient Site

Meta

Find valuable information about ENHERTU® (fam-trastuzumab deruxtecan-nxki), including clinical trial results, safety information, downloadable resources, and more. See the full Important Safety Information, Prescribing Information, including Boxed WARNINGS, and Medication Guide for more information.

H1 What is ENHERTU?
H3 Select a Cancer Type
H3 What is the most important information I should know about ENHERTU?
H3 ENHERTU can cause serious side effects, including:
📝 The Narrative — clean text per page (Info Density · Semantic Coherence)
HOMEPAGE (https://enhertu.com) ENHERTU® (fam-trastuzumab deruxtecan-nxki) | Official Patient Website 
[H1] ENHERTU is FDA-approved for the treatment of several types of cancer

[IMG: callout1]

[IMG: callout1]

HER2+ Metastatic Breast Cancer

[IMG: callout1]

[IMG: callout1]

HER2-Low and HER2-Ultralow Metastatic Breast Cancer

[IMG: callout1]

[IMG: callout1]

HER2+ (IHC 3+) Metastatic Solid Tumors*

[IMG: callout1]

[IMG: callout1]

HER2-Mutant Metastatic Lung Cancer

[IMG: callout1]

[IMG: callout1]

HER2+ Advanced Stomach Cancer

Don’t know your HER2 status? Talk to your healthcare provider.

Not actual patients.
Metastatic is defined as cancer that has spread to other parts of the body.
HER2, human epidermal growth factor receptor 2; HR+, hormone receptor-positive; IHC, immunohistochemistry.
*A solid tumor is a mass of cancer cells that grow in organs, muscles, or bones.

[H1] What is ENHERTU?

ENHERTU is a prescription medicine used to treat adults who have:

human epidermal growth factor receptor 2 (HER2)-positive breast cancer that cannot be removed by surgery or has spread to other parts of the body (metastatic) in combination with pertuzumab as your first treatment. Your healthcare provider will perform a test to make sure ENHERTU in combination with pertuzumab is right for you.
HER2-positive breast cancer that cannot be removed by surgery or that has spread to other parts of the body (metastatic), and who have received a prior anti-HER2 breast cancer treatment for metastatic disease or have breast cancer that has come back during or within 6 months of completing treatment for their early-stage breast cancer.
HER2-low breast cancer that cannot be removed by surgery or that has spread to other parts of the body (metastatic), and who have received a prior chemotherapy for metastatic disease, or whose disease has returned during or within 6 months of completing adjuvant chemotherapy (after surgery). Your healthcare provider will perform a test to make sure ENHERTU is right for you.
Hormone receptor (HR)-positive, HER2-low or HR-positive, HER2-ultralow breast cancer that cannot be removed by surgery or that has spread to other parts of the body (metastatic), and who have received one or more endocrine treatments for metastatic disease. Your healthcare provider will perform a test to make sure ENHERTU is right for you.
non-small cell lung cancer (NSCLC) that has a certain mutation in the HER2 gene and cannot be removed by surgery or has spread to other parts of your body (metastatic), and who have received a prior treatment. Your healthcare provider will perform a test to make sure ENHERTU is right for you.

ENHERTU was FDA approved for this use based on a clinical study that measured how many patients responded and how long they responded. ENHERTU is still being studied to confirm these results.

stomach cancer called gastric or gastroesophageal junction (GEJ) adenocarcinoma that is HER2-positive and has spread to areas near your stomach (locally advanced) or that has spread to other parts of your body (metastatic), and who have received a prior trastuzumab-based regimen.
solid tumors that are HER2-positive (IHC 3+) and that cannot be removed by surgery or have spread to other parts of your body (metastatic), and who have received a prior treatment and have no other satisfactory treatment options. Your healthcare provider will perform a test to make sure ENHERTU is right for you.

ENHERTU was FDA approved for this use based on clinical studies that measured how many patients responded and how long they responded. ENHERTU is still being studied to confirm these results.

It is not known if ENHERTU is safe and effective in children.

Please see full
Prescribing
Information, including Boxed WARNINGS, and Medication Guide.
3881 chars
SUB-PAGE (https://enhertu.com/en/) ENHERTU® (fam-trastuzumab deruxtecan-nxki) | Official Patient Website 
[H1] ENHERTU is FDA-approved for the treatment of several types of cancer

[IMG: callout1]

[IMG: callout1]

HER2+ Metastatic Breast Cancer

[IMG: callout1]

[IMG: callout1]

HER2-Low and HER2-Ultralow Metastatic Breast Cancer

[IMG: callout1]

[IMG: callout1]

HER2+ (IHC 3+) Metastatic Solid Tumors*

[IMG: callout1]

[IMG: callout1]

HER2-Mutant Metastatic Lung Cancer

[IMG: callout1]

[IMG: callout1]

HER2+ Advanced Stomach Cancer

Don’t know your HER2 status? Talk to your healthcare provider.

Not actual patients.
Metastatic is defined as cancer that has spread to other parts of the body.
HER2, human epidermal growth factor receptor 2; HR+, hormone receptor-positive; IHC, immunohistochemistry.
*A solid tumor is a mass of cancer cells that grow in organs, muscles, or bones.

[H1] What is ENHERTU?

ENHERTU is a prescription medicine used to treat adults who have:

human epidermal growth factor receptor 2 (HER2)-positive breast cancer that cannot be removed by surgery or has spread to other parts of the body (metastatic) in combination with pertuzumab as your first treatment. Your healthcare provider will perform a test to make sure ENHERTU in combination with pertuzumab is right for you.
HER2-positive breast cancer that cannot be removed by surgery or that has spread to other parts of the body (metastatic), and who have received a prior anti-HER2 breast cancer treatment for metastatic disease or have breast cancer that has come back during or within 6 months of completing treatment for their early-stage breast cancer.
HER2-low breast cancer that cannot be removed by surgery or that has spread to other parts of the body (metastatic), and who have received a prior chemotherapy for metastatic disease, or whose disease has returned during or within 6 months of completing adjuvant chemotherapy (after surgery). Your healthcare provider will perform a test to make sure ENHERTU is right for you.
Hormone receptor (HR)-positive, HER2-low or HR-positive, HER2-ultralow breast cancer that cannot be removed by surgery or that has spread to other parts of the body (metastatic), and who have received one or more endocrine treatments for metastatic disease. Your healthcare provider will perform a test to make sure ENHERTU is right for you.
non-small cell lung cancer (NSCLC) that has a certain mutation in the HER2 gene and cannot be removed by surgery or has spread to other parts of your body (metastatic), and who have received a prior treatment. Your healthcare provider will perform a test to make sure ENHERTU is right for you.

ENHERTU was FDA approved for this use based on a clinical study that measured how many patients responded and how long they responded. ENHERTU is still being studied to confirm these results.

stomach cancer called gastric or gastroesophageal junction (GEJ) adenocarcinoma that is HER2-positive and has spread to areas near your stomach (locally advanced) or that has spread to other parts of your body (metastatic), and who have received a prior trastuzumab-based regimen.
solid tumors that are HER2-positive (IHC 3+) and that cannot be removed by surgery or have spread to other parts of your body (metastatic), and who have received a prior treatment and have no other satisfactory treatment options. Your healthcare provider will perform a test to make sure ENHERTU is right for you.

ENHERTU was FDA approved for this use based on clinical studies that measured how many patients responded and how long they responded. ENHERTU is still being studied to confirm these results.

It is not known if ENHERTU is safe and effective in children.

Please see full
Prescribing
Information, including Boxed WARNINGS, and Medication Guide.
3881 chars
SUB-PAGE (https://enhertu.com/en/breast/) ENHERTU® (fam-trastuzumab deruxtecan-nxki) | HER2+ Metastatic Breast Cancer Patient Site 
[IMG: Hopeful woman at beach looking at camera]

[IMG: Hopeful woman at beach looking at camera]

For certain adults with HER2-positive metastatic breast cancer (mBC)

[H1] Sure, HER2-positive metastatic breast cancer will try to take it all. But

NOT TODAY
NOT TODAY

See clinical trial results

Metastatic is defined as cancer that has spread to other parts of the body.

HER2, human epidermal growth factor receptor 2.

Not an actual patient.

Not an actual patient.

See clinical trial results

Metastatic is defined as cancer that has spread to other parts of the body.
HER2, human epidermal growth factor receptor 2.

ENHERTU in combination with pertuzumab is the biggest breakthrough for people starting HER2-positive metastatic breast cancer treatment in over a decade*

*Compared to a taxane-based chemotherapy, Herceptin® (trastuzumab), and pertuzumab combination. Visit the results page to learn more.

[H1] What is ENHERTU?

ENHERTU (en-HER-too)

is a prescription medicine used to treat adults with:

Human epidermal growth factor receptor 2 (HER2)-positive breast cancer that cannot be removed by surgery or has spread to other parts of the body (metastatic) in combination with pertuzumab as your first treatment. Your healthcare provider will perform a test to make sure ENHERTU in combination with pertuzumab is right for you.

ENHERTU alone is a prescription medicine used to treat adults with:

HER2-positive breast cancer that cannot be removed by surgery or that has spread to other parts of the body (metastatic), and who have received a prior anti-HER2 breast cancer treatment:

for metastatic disease, or
have breast cancer that has come back during or within 6 months of completing treatment for their early-stage breast cancer.

It is not known if ENHERTU is safe and effective in children.

[H3] What is the most important information I should know
about ENHERTU?

[H3] ENHERTU can cause serious side effects, including:

Lung problems that may be severe, life-threatening or
that may lead to death. If you develop lung problems your healthcare provider may
treat you with corticosteroid medicines. Tell your healthcare provider right away if you get any of the following signs and symptoms, which can be viewed by clicking here.

Please see full Prescribing
Information, including Boxed WARNINGS, and Medication Guide.

[IMG: Support and resources icon]

Financial support and downloadable resources

Get more support

[IMG: Sign up for information email]

Would you like to receive updates about ENHERTU?

Sign up for information
2901 chars
SUB-PAGE (https://enhertu.com/en/her2-low-breast/) ENHERTU® (fam-trastuzumab deruxtecan-nxki) | Metastatic Breast Cancer Patient Site 
[IMG: Photo of a woman looking straight ahead. The photo reads, “NOT TODAY.]

[IMG: Photo of a woman looking straight ahead. The photo reads, “NOT TODAY.]

For certain adults with HR+, HER2-low or HR+, HER2-ultralow, metastatic breast cancer (mBC) who received prior endocrine treatment in the metastatic setting

Sure, HER2-low and HR+, HER2-ultralow metastatic breast cancer will try to take it all. But

NOT TODAY
NOT TODAY

Previously diagnosed with HER2-negative metastatic breast cancer (mBC)? You may actually have low levels of HER2
Learn more

Metastatic is defined as cancer that has spread to other parts of the body.
HER2, human epidermal growth factor receptor 2; HR+, hormone receptor-positive.

Not an actual patient.

Not an actual patient.

Previously diagnosed with HER2-negative metastatic breast cancer (mBC)? You may actually have low levels of HER2

Learn more

Metastatic is defined as cancer that has spread to other
parts of the body.
HER2, human epidermal growth factor receptor 2; HR+, hormone receptor-positive.

Not an actual patient.

[H1] What is ENHERTU?
ENHERTU (en-HER-too)

is a prescription medicine used to treat adults who have:

HER2-low breast cancer that cannot be removed by surgery or that has spread to other parts of the body (metastatic), and who have received a prior chemotherapy for metastatic disease, or whose disease has returned during or within 6 months of completing adjuvant chemotherapy (after surgery). Your healthcare provider will perform a test to make sure ENHERTU is right for you.
Hormone receptor (HR)-positive, HER2-low or HR-positive, HER2-ultralow breast cancer that cannot be removed by surgery or that has spread to other parts of the body (metastatic), and who have received one or more endocrine treatments for metastatic disease. Your healthcare provider will perform a test to make sure ENHERTU is right for you.
It is not known if ENHERTU is safe and effective in children.

[H3] What is the most important information I should know
about ENHERTU?

[H3] ENHERTU can cause serious side effects, including:

Lung problems that may be severe, life-threatening or that may lead to death. If you develop lung problems your healthcare provider may treat you with corticosteroid medicines. Tell your healthcare provider right away if you get any of the following signs
and symptoms:
Please see full Prescribing
Information, including Boxed WARNINGS, and Medication Guide.

[IMG: Learn more about ENHERTU4U]

Financial support and downloadable resources

Get more support

[IMG: Sign up for information]

Would you like to receive updates about ENHERTU?

Sign up for information
2795 chars
🛡️ Trust Signals — reviews, proof links, trust-theatre flag (Trust & Proof)
0Review mentions (all pages)
0External proof links (all pages)
PageReviewsProof links
/ (home) 0 0
/en/ 0 0
/en/breast/ 0 0
/en/her2-low-breast/ 0 0
🔗 Identity & Technical Layer — schema JSON-LD: identity chains, entity gaps (Identity & Authority)
Homepage schema 
{
    "@context": "https://schema.org/",
    "@type": "MedicalWebPage",
    "url": "https://www.enhertu.com/",
    "audience": "https://health-lifesci.schema.org/Patient",
    "creator": {
        "@type": "Organization",
        "name": "Daiichi Sankyo, Inc",
        "url": "https://daiichisankyo.us",
        "logo": "https://daiichisankyo.us/home",
        "sameAs": "https://en.wikipedia.org/wiki/Daiichi_Sankyo"
    },
    "mainEntity": {
        "@type": "Drug",
        "name": "ENHERTU",
        "sameAs": "https://en.wikipedia.org/wiki/Trastuzumab_deruxtecan",
        "image": "https://www.enhertu.com/-/media/enhertu_patient/images/gateway/enhertu-logo.ashx",
        "legalStatus": "FDA Approved",
        "activeIngredient": "fam-trastuzumab deruxtecan-nxki",
        "nonProprietaryName": "fam-trastuzumab deruxtecan-nxki",
        "isProprietary": "True",
        "isAvailableGenerically": "False",
        "relevantSpecialty": "https://health-lifesci.schema.org/Oncologic",
        "manufacturer": {
            "@type": "Organization",
            "name": "Daiichi Sankyo, Inc",
            "url": "https://daiichisankyo.us",
            "logo": "https://daiichisankyo.us/home",
            "sameAs": "https://en.wikipedia.org/wiki/Daiichi_Sankyo"
        },
        "description": "Learn more about ENHERTU® (famtrastuzumab deruxtecan-nxki) for several types of cancer. See Full Safety and Boxed WARNINGS for more information.",
        "drugUnit": "100 mg lyophilized powder in a single-dose vial",
        "dosageForm": "Injection for Intravenous Use",
        "labelDetails": "https://daiichisankyo.us/prescribing-information-portlet/getPIContent?productName=Enhertu&inline=true",
        "administrationRoute": "IV infusion",
        "prescriptionStatus": "https://health-lifesci.schema.org/PrescriptionOnly",
        "prescribingInfo": "https://daiichisankyo.us/prescribing-information-portlet/getPIContent?productName=Enhertu&inline=true",
        "foodWarning": "",
        "alcoholWarning": "",
        "pregnancyWarning": "Harm to your unborn baby. Tell your healthcare provider right away if you become pregnant or think you might be pregnant during treatment with ENHERTU. If you are able to become pregnant, your healthcare provider should do a pregnancy test before you start treatment with ENHERTU. Females who are able to become pregnant should use effective birth control (contraception) during treatment with ENHERTU and for at least 7 months after the last dose. Males who have female partners that are able to become pregnant should use effective birth control (contraception) during treatment with ENHERTU and for at least 4 months after the last dose.",
        "breastfeedingWarning": "Before you receive ENHERTU, tell your healthcare provider about all of your medical conditions, including if you are breastfeeding or plan to breastfeed. It is not known if ENHERTU passes into your breast milk. Do not breastfeed during treatment with ENHERTU and for 7 months after the last dose.",
        "mechanismOfAction": "As a targeted treatment called an antibody-drug conjugate (ADC), ENHERTU is designed to work differently than traditional chemotherapies. 1. ENHERTU is made up of an antibody with the chemotherapy attached 2. The antibody part of ENHERTU targets and attaches to HER2 on the cancer cell 3. ENHERTU enters the cancer cell and the chemotherapy is released 4. The chemotherapy part of ENHERTU helps destroy the cancer cell as well as other cells nearby Although ENHERTU is designed to target HER2 on cancer cells, it may affect some healthy cells. ENHERTU may not work for everyone.",
        "interactingDrug": ""
    },
    "about": [
        {
            "@type": "MedicalCondition",
            "name": "HER2+ Metastatic Breast Cancer",
            "alternateName": "HER2+ mBC",
            "associatedAnatomy": {
                "@type": "AnatomicalStructure",
                "name": "Breast"
            },
            "relevantSpecialty": "https://health-lifesci.schema.org/Oncologic",
            "possibleTreatment": {
                "@type": "MedicalTherapy",
                "drug": {
                    "@type": "Drug",
                    "name": "ENHERTU"
                }
            }
        },
        {
            "@type": "MedicalCondition",
            "name": "HER2+ Advanced Stomach Cancer",
            "alternateName": "HER2+ aGC",
            "associatedAnatomy": {
                "@type": "AnatomicalStructure",
                "name": "Stomach"
            },
            "relevantSpecialty": "https://health-lifesci.schema.org/Oncologic",
            "possibleTreatment": {
                "@type": "MedicalTherapy",
                "drug": {
                    "@type": "Drug",
                    "name": "ENHERTU"
                }
            }
        },
        {
            "@type": "MedicalCondition",
            "name": "HER2 Mutant Metastatic Lung Cancer",
            "alternateName": "HER2 Mutant NSCLC",
            "associatedAnatomy": {
                "@type": "AnatomicalStructure",
                "name": "Lung"
            },
            "relevantSpecialty": "https://health-lifesci.schema.org/Oncologic",
            "possibleTreatment": {
                "@type": "MedicalTherapy",
                "drug": {
                    "@type": "Drug",
                    "name": "ENHERTU"
                }
            }
        },
        {
            "@type": "MedicalCondition",
            "name": "HER2-low Metastatic Breast Cancer",
            "alternateName": "HER2-low mBC",
            "associatedAnatomy": {
                "@type": "AnatomicalStructure",
                "name": "Breast"
            },
            "relevantSpecialty": "https://health-lifesci.schema.org/Oncologic",
            "possibleTreatment": {
                "@type": "MedicalTherapy",
                "drug": {
                    "@type": "Drug",
                    "name": "ENHERTU"
                }
            }
        }
    ]
}
/en/ 
{
    "@context": "https://schema.org/",
    "@type": "MedicalWebPage",
    "url": "https://www.enhertu.com/",
    "audience": "https://health-lifesci.schema.org/Patient",
    "creator": {
        "@type": "Organization",
        "name": "Daiichi Sankyo, Inc",
        "url": "https://daiichisankyo.us",
        "logo": "https://daiichisankyo.us/home",
        "sameAs": "https://en.wikipedia.org/wiki/Daiichi_Sankyo"
    },
    "mainEntity": {
        "@type": "Drug",
        "name": "ENHERTU",
        "sameAs": "https://en.wikipedia.org/wiki/Trastuzumab_deruxtecan",
        "image": "https://www.enhertu.com/-/media/enhertu_patient/images/gateway/enhertu-logo.ashx",
        "legalStatus": "FDA Approved",
        "activeIngredient": "fam-trastuzumab deruxtecan-nxki",
        "nonProprietaryName": "fam-trastuzumab deruxtecan-nxki",
        "isProprietary": "True",
        "isAvailableGenerically": "False",
        "relevantSpecialty": "https://health-lifesci.schema.org/Oncologic",
        "manufacturer": {
            "@type": "Organization",
            "name": "Daiichi Sankyo, Inc",
            "url": "https://daiichisankyo.us",
            "logo": "https://daiichisankyo.us/home",
            "sameAs": "https://en.wikipedia.org/wiki/Daiichi_Sankyo"
        },
        "description": "Learn more about ENHERTU® (famtrastuzumab deruxtecan-nxki) for several types of cancer. See Full Safety and Boxed WARNINGS for more information.",
        "drugUnit": "100 mg lyophilized powder in a single-dose vial",
        "dosageForm": "Injection for Intravenous Use",
        "labelDetails": "https://daiichisankyo.us/prescribing-information-portlet/getPIContent?productName=Enhertu&inline=true",
        "administrationRoute": "IV infusion",
        "prescriptionStatus": "https://health-lifesci.schema.org/PrescriptionOnly",
        "prescribingInfo": "https://daiichisankyo.us/prescribing-information-portlet/getPIContent?productName=Enhertu&inline=true",
        "foodWarning": "",
        "alcoholWarning": "",
        "pregnancyWarning": "Harm to your unborn baby. Tell your healthcare provider right away if you become pregnant or think you might be pregnant during treatment with ENHERTU. If you are able to become pregnant, your healthcare provider should do a pregnancy test before you start treatment with ENHERTU. Females who are able to become pregnant should use effective birth control (contraception) during treatment with ENHERTU and for at least 7 months after the last dose. Males who have female partners that are able to become pregnant should use effective birth control (contraception) during treatment with ENHERTU and for at least 4 months after the last dose.",
        "breastfeedingWarning": "Before you receive ENHERTU, tell your healthcare provider about all of your medical conditions, including if you are breastfeeding or plan to breastfeed. It is not known if ENHERTU passes into your breast milk. Do not breastfeed during treatment with ENHERTU and for 7 months after the last dose.",
        "mechanismOfAction": "As a targeted treatment called an antibody-drug conjugate (ADC), ENHERTU is designed to work differently than traditional chemotherapies. 1. ENHERTU is made up of an antibody with the chemotherapy attached 2. The antibody part of ENHERTU targets and attaches to HER2 on the cancer cell 3. ENHERTU enters the cancer cell and the chemotherapy is released 4. The chemotherapy part of ENHERTU helps destroy the cancer cell as well as other cells nearby Although ENHERTU is designed to target HER2 on cancer cells, it may affect some healthy cells. ENHERTU may not work for everyone.",
        "interactingDrug": ""
    },
    "about": [
        {
            "@type": "MedicalCondition",
            "name": "HER2+ Metastatic Breast Cancer",
            "alternateName": "HER2+ mBC",
            "associatedAnatomy": {
                "@type": "AnatomicalStructure",
                "name": "Breast"
            },
            "relevantSpecialty": "https://health-lifesci.schema.org/Oncologic",
            "possibleTreatment": {
                "@type": "MedicalTherapy",
                "drug": {
                    "@type": "Drug",
                    "name": "ENHERTU"
                }
            }
        },
        {
            "@type": "MedicalCondition",
            "name": "HER2+ Advanced Stomach Cancer",
            "alternateName": "HER2+ aGC",
            "associatedAnatomy": {
                "@type": "AnatomicalStructure",
                "name": "Stomach"
            },
            "relevantSpecialty": "https://health-lifesci.schema.org/Oncologic",
            "possibleTreatment": {
                "@type": "MedicalTherapy",
                "drug": {
                    "@type": "Drug",
                    "name": "ENHERTU"
                }
            }
        },
        {
            "@type": "MedicalCondition",
            "name": "HER2 Mutant Metastatic Lung Cancer",
            "alternateName": "HER2 Mutant NSCLC",
            "associatedAnatomy": {
                "@type": "AnatomicalStructure",
                "name": "Lung"
            },
            "relevantSpecialty": "https://health-lifesci.schema.org/Oncologic",
            "possibleTreatment": {
                "@type": "MedicalTherapy",
                "drug": {
                    "@type": "Drug",
                    "name": "ENHERTU"
                }
            }
        },
        {
            "@type": "MedicalCondition",
            "name": "HER2-low Metastatic Breast Cancer",
            "alternateName": "HER2-low mBC",
            "associatedAnatomy": {
                "@type": "AnatomicalStructure",
                "name": "Breast"
            },
            "relevantSpecialty": "https://health-lifesci.schema.org/Oncologic",
            "possibleTreatment": {
                "@type": "MedicalTherapy",
                "drug": {
                    "@type": "Drug",
                    "name": "ENHERTU"
                }
            }
        }
    ]
}
/en/breast/ — no schema detected (entity gap)
/en/her2-low-breast/ 
{
    "@context": "https://schema.org/",
    "@type": "MedicalWebPage",
    "url": "https://www.enhertu.com/en/her2-low-breast",
    "description": "Learn about ENHERTU® (fam-trastuzumab deruxtecan-nxki), including clinical trial results and safety data. See the full Important Safety Information, Prescribing Information, including Boxed WARNINGS, and Medication Guide for more information.",
    "sameAs": "https://en.wikipedia.org/wiki/Trastuzumab_deruxtecan",
    "medicalAudience": "https://health-lifesci.schema.org/Patient",
    "creator": {
        "@type": "Organization",
        "name": "Daiichi Sankyo, Inc",
        "url": "https://daiichisankyo.us/home",
        "logo": "https://enhertu.com/-/media/enhertu_patient/images/footer/daiichi-sankyo-astra-zeneca-logo.ashx",
        "sameAs": "https://en.wikipedia.org/wiki/Daiichi_Sankyo"
    },
    "specialty": [
        "https://health-lifesci.schema.org/Oncologic",
        "https://schema.org/Oncologic"
    ],
    "mainEntity": {
        "@id": "https://enhertu.com/en/her2-low-breast#Drug",
        "@type": "Drug",
        "name": "ENHERTU",
        "brand": {
            "@type": "Brand",
            "name": "ENHERTU",
            "logo": "https://enhertu.com/-/media/enhertu_patient/images/header/enhertu-logo.ashx",
            "description": "Find valuable information about ENHERTU® (fam-trastuzumab deruztecan-nxki), including clinical trial results, safety information, downloadable resources, and more. See Full Safety, Boxed WARNINGS, & Medication Guide for more information.",
            "sameAs": "https://en.wikipedia.org/wiki/Trastuzumab_deruxtecan"
        },
        "isProprietary": "True",
        "isAvailableGenerically": "False",
        "nonProprietaryName": "fam-trastuzumab deruxtecan-nxki",
        "activeIngredient": "fam-trastuzumab deruxtecan-nxki",
        "administrationRoute": "IV infusion",
        "alcoholWarning": "N/A",
        "breastfeedingWarning": "Before you receive ENHERTU, tell your healthcare provider about all of your medical conditions, including if you:\n  o have lung or breathing problems\n  o have signs or symptoms of an infection\n  o have or have had any heart problems\n  o are breastfeeding or plan to breastfeed. It is not known if ENHERTU passes into your breast milk. Do not breastfeed during treatment with ENHERTU and for 7 months after the last dose.",
        "dosageForm": "Injection for intravenous use",
        "drugUnit": "100 mg lyophilized powder in a single-dose vial",
        "foodWarning": "N/A",
        "labelDetails": "https://daiichisankyo.us/prescribing-information-portlet/getPIContent?productName=Enhertu&inline=true",
        "mechanismOfAction": "As a targeted treatment called an antibody-drug conjugate (ADC), ENHERTU is designed to work differently than traditional chemotherapies. \n\n1. ENHERTU is made up of an antibody with the chemotherapy attached \n2. The antibody part of ENHERTU targets and attaches to HER2 on the cancer cell \n3. ENHERTU enters the cancer cell and the chemotherapy is released  \n4. The chemotherapy part of ENHERTU helps destroy the cancer cell as well as other cells nearby \n\nAlthough ENHERTU is designed to target HER2 on cancer cells, it may affect some healthy cells. ENHERTU may not work for everyone.",
        "prescribingInfo": "https://daiichisankyo.us/prescribing-information-portlet/getPIContent?productName=Enhertu&inline=true",
        "prescriptionStatus": "https://health-lifesci.schema.org/PrescriptionOnly",
        "manufacturer": {
            "@type": "Organization",
            "name": "Daiichi Sankyo, Inc",
            "url": "https://www.daiichisankyo.us",
            "logo": "https://daiichisankyo.us/documents/d/dsi/logo",
            "sameAs": "https://en.wikipedia.org/wiki/Daiichi_Sankyo"
        },
        "pregnancyWarning": "• Harm to your unborn baby. Tell your healthcare provider right away if you become pregnant or think you might be pregnant during treatment with ENHERTU. \n  o If you are able to become pregnant, your healthcare provider should do a pregnancy test before you start treatment with ENHERTU. \n  o Females who are able to become pregnant should use effective birth control (contraception) during treatment with ENHERTU and for 7 months after the last dose. \n  o Males who have female partners that are able to become pregnant should use effective birth control (contraception) during treatment with ENHERTU and for 4 months after the last dose.",
        "interactingDrug": "N/A",
        "doseSchedule": {
            "@type": "DoseSchedule",
            "doseUnit": "mg/kg",
            "doseValue": "5.4",
            "frequency": "Once every 3 weeks",
            "targetPopulation": "Adults"
        }
    },
    "about": {
        "@type": "MedicalCondition",
        "name": "HER2-low and HR+, HER2-ultralow Metastatic Breast Cancer",
        "alternateName": "HER2-low and HR+, HER2-ultralow mBC",
        "associatedAnatomy": {
            "@type": "AnatomicalStructure",
            "name": "Breast"
        },
        "possibleTreatment": {
            "@id": "https://enhertu.com/en/her2-low-breast#Drug"
        }
    }
}

Your Diagnosis

Before revealing the machine’s verdict, predict the BS score for each signal. Higher = more BS (more fluff, less verifiable substance). Drag each slider, then submit to compare your judgment against the engine.

Information Density 0 / 30
Read the Narrative & headings: do hard facts (prices, dates, numbers) outweigh fluff power-words?
Semantic Coherence 0 / 20
Compare the homepage promise against the sub-page reality. Do they hold the same line?
Trust & Proof 0 / 20
Weigh review mentions against actual external proof links. Claims without verification = theatre.
Commodity Fingerprint 0 / 15
Check headings & narrative against the industry clichés in the setup above.
Identity & Authority 0 / 15
Inspect the schema: is there real Organization/Person identity with sameAs links, or gaps?
Your predicted BS score 0 / 100
💡 Stuck? Reveal the heuristic lens — how the deterministic page-auditor reads each signal (no AI, pure pattern rules)

These are the structural rules a local, deterministic auditor applies — the same lens you can use to judge each signal. They describe what to look for, not this company’s result.

Information Density

Classify each sentence as substantive or hollow. Grounding markers — numbers, currencies, dates, technical units, named entities — outweigh marketing adjectives. When fluff sits right next to hard evidence, the fluff is forgiven.

Semantic Alignment

Pull the main entities out of the H1, then check whether they actually recur through the body. A page that announces one thing and then talks about another drifts. Headings with no real sentences underneath read as pseudo-substance.

Trust & Proof

Count trust words (review, testimonial, rating, verified) against real outbound proof links (Google, Trustpilot, Clutch, G2, Yelp). Lots of trust language with zero verification links is trust theatre. Unlinked logo galleries count against it.

Commodity Fingerprint

Look at how much sentence length varies. Natural writing varies its rhythm; templated or mass-produced copy is statistically uniform. Very low variation reads as commodity content — unless unique named entities break the pattern.

Identity & Authority

Inspect the JSON-LD. Is there an Organization or Person schema, and does it carry sameAs links to real external profiles (LinkedIn, socials)? Missing schema or no identity declaration signals an anonymous entity.

Want to apply this lens yourself? The free BS Indicator Chrome extension runs these heuristic checks live on any page. Bear in mind it is a single-page, deterministic tool — it relies only on pattern rules for the page in front of it and does not perform the cross-page semantic correlation this audit uses, so its readout is a starting lens, not the full verdict.

B
BS Level
Medical Devices, Pharma & Biotech
40.7 Avg BS

Based on 784 businesses audited.

BS Detector

Medical Devices, Pharma & Biotech BS: ENHERTU (Daiichi Sankyo, Inc.) (enhertu.com)

https://enhertu.com 📍 Industry: Medical Devices, Pharma & Biotech
10 BS / 100

This is a benchmark for low-BS communication in the pharmaceutical space. It replaces marketing hyperbole with regulatory precision, providing dense technical evidence and clear safety boundaries for every claim made.

Info Density Power-words vs. Substance ratio.
5
17% BS
Semantic Coherence Homepage promise vs. Sub-page reality.
0
0% BS
Trust & Proof Verifiable evidence vs. Trust Theatre.
1
5% BS
Commodity Fingerprint Detection of industry clichés/templates.
4
27% BS
Identity & Authority Expert verifiability & Schema depth.
0
0% BS

To reach a near-zero score, replace the emotional H1 ‘Sure, HER2-positive metastatic breast cancer will try to take it all’ with a direct clinical outcome statement. Move the clinical trial comparison footnote (comparing against taxane-based chemotherapy) directly into the body text to reduce reliance on small-print verification. Ensure all clinical trial claims link directly to ClinicalTrials.gov registry numbers for maximum transparency. Finally, remove the marketing term ‘breakthrough’ in favor of specific statistical significance data in the hero section.

The site perfectly matches the Pharma & Biotech category, focusing on a specific prescription medicine with detailed clinical indications. The content is heavily structured around regulatory requirements, including FDA approval statuses and pharmacovigilance safety information.

“The score of 10 was primarily driven by Information Density and Commodity Fingerprint, reflecting the presence of standard marketing slogans ('Not Today') and pharma-industry clichés ('breakthrough'). All other pillars scored near zero due to the site's intense focus on clinical evidence, regulatory compliance, and robust structured data.”

Verified Analysis Date: June 20, 2026 © 1EuroSEO Independent Evaluator — Non-Sponsored Result
Analysis Disclosure & Source Attribution

This training module utilizes a snapshot of public data from ENHERTU (Daiichi Sankyo, Inc.), captured on June 20, 2026, to demonstrate how machine logic evaluates different types of business narratives.

Purpose: This data is presented under “Fair Use” / “Educational Exception” for the purpose of forensic semantic analysis, allowing users to compare human intuition against machine-generated evaluations.

Notice to ENHERTU (Daiichi Sankyo, Inc.): This analysis is part of a non-adversarial audit conducted by 1 Euro SEO. The results provided by 1EuroSEO are intended as professional feedback to help improve any website’s machine-readability and authority signals. The 1EuroSEO BS Detection Tool is a free tool, and anyone can test any company to see how their content is interpreted by AI models.

Any company can use the insights for free and improve its voice by comparing it to industry clichés or competitors. When a company has updated its content, it can always submit a new audit request, which will be reflected in a new current score.

To all users: You are encouraged to visit the live site at https://enhertu.com to view the most current version of its content and learn from the source what this company is about and what it offers.